Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
minocycline capsule (100mg) per day orally
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China
RECRUITINGChange of cystoid macular edema
Change of CME measured by Optical coherence tomography (OCT)
Time frame: At 6 months
Change of best corrected visual acuity (BCVA)
Change of BCVA measured by the Early Treatment Diabetic Retinopathy Study
Time frame: At 6 months
Change of macular sensitivity
Change of BCVA measured by Macular Integrity Assessment (MAIA)
Time frame: At 6 months
Change of retinal vascular leakage
Change of retinal vascular leakage measured by Fundus fluorescein angiography (FFA) or indocyanine green angiography (ICGA)
Time frame: At 6 months
Change of macular vessel
Change of macular vessel measured by optical coherence tomography angiography (OCTA)
Time frame: At 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.